CRSP241129C57000
- 0.10
- +0.01+11.11%
CRISPR Therapeutics Newsroom
CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Truist Financial Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now
Crispr Therapeutics Management to Meet With Piper Sandler
CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
Cathie Wood's ARK Investment Bought 178.1K Shares of Crispr Therapeutics Today
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
ARKK's Holdings Ranked by SA Quant Grades
Form 144 | CRISPR Therapeutics(CRSP.US) Officer Proposes to Sell 4.11 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $CRISPR Therapeutics(CRSP.US)$ Officer Dr. Samarth Kulkarni intends to sell 75,000 shares of its common stock on Nov 11, with a total market value of approximately $4.1
Cathie Wood's ARK Innovation ETF Is a Trump Trade Winner as Tesla Soars. But It Still Lags the Market.
Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich's Ataxia Next-Generation Gene Therapy
Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Positive Outlook on Crispr Therapeutics AG Driven by Strong Pricing and Strategic Partnerships
CRISPR, Beam, Other Gene Editing Names up Significantly
Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $95